Identifying Patients With gBRCA Mutations

Mutations in gBRCA may be present in many types of patients with metastatic breast cancer (MBC)2*
  • Not all have triple-negative disease
  • Not all are young
  • Not all are white
  • Not all are women
*According to a retrospective real-world analysis of clinical outcomes, treatment patterns, and health resource utilization among 229 patients diagnosed with HER2- gBRCA1/2-mutated MBC between January 2011 and February 2018.2
Whom to test
Test patients with recurrent or metastatic breast cancer for gBRCA mutations to inform treatment planning3
Genetic testing icon
Test based on age, family history, and other considerations
According to the NCCN Guidelines® for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, BRCA1/2 testing is recommended for patients with a breast cancer diagnosis who meet certain criteria, including but not limited to4:
  • Breast cancer diagnosed at ≤45 years of age
  • TNBC diagnosed at ≤60 years of age
  • A known mutation in a cancer susceptibility gene within the family
  • A mutation identified on tumor genomic testing that has clinical implications if also identified in the germline
  • To aid in systemic therapy decision-making, such as for HER2– MBC
View the complete guidelines and testing criteria at NCCN.org.
Testing is clinically indicated for patients with a personal history of certain cancers to aid in systemic therapy decision-making, such as for HER2– MBC
May include breast, ovarian, pancreatic, and prostate cancer. Please see detailed criteria for testing for high-penetrance breast and/or ovarian cancer susceptibility genes (such as BRCA1/2) in the NCCN Guidelines® for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic.
Identifying patients icon
Test based on disease stage
According to the NCCN Guidelines® for Breast Cancer, all patients with recurrent or metastatic breast cancer should be assessed for gBRCA1/2 mutations to identify candidates for PARP inhibitor therapy.3
REFERENCES
  1. TALZENNA [prescribing information]. New York, NY: Pfizer Inc.; 2020.
  2. Quek RGW, Mardekian J. Clinical outcomes, treatment patterns, and health resource utilization among metastatic breast cancer patients with germline BRCA1/2 mutation: a real-world retrospective study. Adv Ther. 2019;36(3):708-720. doi.org/10.1007/s12325-018-0867-x.
  3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.4.2020. © 2020 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed June 8, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic V.1.2020. © 2020 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed March 23, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.